Nermin Akdemir1, Cemil Bilir2. 1. Department of Gynecology and Obstetrics, Keçiören Teaching and Research Hospital, Ankara, Turkey. 2. Department of Internal Medicine, Faculty of Medicine, Zonguldak Karaelmas Universtiy, Zonguldak, Turkey.
Abstract
OBJECTIVE: In this study we investigate the possible relation of thyroid dysfunction and thyroid antibodies to hyperemesis gravidarum. MATERIAL AND METHODS: Thirty-seven patients with hyperemesis gravidarum and 33 healthy controls have been included in this study. RESULTS: Thyroid dysfunction was significantly more common than in controls (38% vs 6%, p=0.002). Thyroglobulin antibodies were also significantly more common in patients with hyperemesis gravidarum than controls (54 IU/mL vs. 14 IU/mL, p=0.03). CONCLUSION: Hyperemesis gravidarum can be a risk factor for postpartum thyroid dysfunction. Thyroid antibodies must be checked in the hyperemesis population in an endemic goitre region and/or iodine replacement regions.
OBJECTIVE: In this study we investigate the possible relation of thyroid dysfunction and thyroid antibodies to hyperemesis gravidarum. MATERIAL AND METHODS: Thirty-seven patients with hyperemesis gravidarum and 33 healthy controls have been included in this study. RESULTS:Thyroid dysfunction was significantly more common than in controls (38% vs 6%, p=0.002). Thyroglobulin antibodies were also significantly more common in patients with hyperemesis gravidarum than controls (54 IU/mL vs. 14 IU/mL, p=0.03). CONCLUSION:Hyperemesis gravidarum can be a risk factor for postpartum thyroid dysfunction. Thyroid antibodies must be checked in the hyperemesis population in an endemic goitre region and/or iodine replacement regions.
Entities:
Keywords:
Hyperemesis gravidarum; thyroid function
Authors: Brian M Casey; Jodi S Dashe; C Edward Wells; Donald D McIntire; William Byrd; Kenneth J Leveno; F Gary Cunningham Journal: Obstet Gynecol Date: 2005-02 Impact factor: 7.661
Authors: Elizabeth N Pearce; Emily Oken; Matthew W Gillman; Stephanie L Lee; Barbarajean Magnani; Deborah Platek; Lewis E Braverman Journal: Endocr Pract Date: 2008 Jan-Feb Impact factor: 3.443
Authors: K Yamazaki; K Sato; K Shizume; Y Kanaji; Y Ito; T Obara; T Nakagawa; T Koizumi; R Nishimura Journal: J Clin Endocrinol Metab Date: 1995-02 Impact factor: 5.958
Authors: A Stagnaro-Green; S H Roman; R H Cobin; E el-Harazy; S Wallenstein; T F Davies Journal: J Clin Endocrinol Metab Date: 1992-03 Impact factor: 5.958